title: Infection and inflammation induce LDL oxidation in vivo.
abstract: Epidemiological studies have shown an increased incidence of coronary artery disease in patients with chronic infections and inflammatory disorders. Because oxidative modification of lipoproteins plays a major role in atherosclerosis, the present study was designed to test the hypothesis that the host response to infection and inflammation induces lipoprotein oxidation in vivo. Lipoprotein oxidation was measured in 3 distinct models of infection and inflammation. Syrian hamsters were injected with bacterial lipopolysaccharide (LPS), zymosan, or turpentine to mimic acute infection, acute systemic inflammation, and acute localized inflammation, respectively. Levels of oxidized fatty acids in serum and lipoprotein fractions were measured by determining levels of conjugated dienes, thiobarbituric acid-reactive substances, and lipid hydroperoxides. Our results demonstrate a significant increase in conjugated dienes and thiobarbituric acid-reactive substances in serum in all 3 models. Moreover, LPS and zymosan produced a 4-fold to 6-fold increase in conjugated diene and lipid hydroperoxide levels in LDL fraction. LPS also produced a 17-fold increase in LDL content of lysophosphatidylcholine that is formed during the oxidative modification of LDL. Finally, LDL isolated from animals treated with LPS was significantly more susceptible to ex vivo oxidation with copper than LDL isolated from saline-treated animals, and a 3-fold decrease occurred in the lag phase of oxidation. These results demonstrate that the host response to infection and inflammation increases oxidized lipids in serum and induces LDL oxidation in vivo. Increased LDL oxidation during infection and inflammation may promote atherogenesis and could be a mechanism for increased incidence of coronary artery disease in patients with chronic infections and inflammatory disorders.
authors.affiliation: Department of Medicine, University of California San Francisco, CA, USA. rmemon@itsa.ucsf.edu
authors.forename: R A
authors.initials: RA
authors.lastname: Memon
authors.forename: I
authors.initials: I
authors.lastname: Staprans
authors.forename: M
authors.initials: M
authors.lastname: Noor
authors.forename: W M
authors.initials: WM
authors.lastname: Holleran
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: A H
authors.initials: AH
authors.lastname: Moser
authors.forename: K R
authors.initials: KR
authors.lastname: Feingold
authors.forename: C
authors.initials: C
authors.lastname: Grunfeld
mesh_terms: D000818:Animals; D008078:Cholesterol, LDL / Q000097:blood; D006224:Cricetinae; D007239:Infections / Q000097:blood* / Q000139:chemically induced; D007249:Inflammation / Q000097:blood* / Q000139:chemically induced; D015227:Lipid Peroxidation; D008070:Lipopolysaccharides; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008244:Lysophosphatidylcholines / Q000097:blood; D008297:Male; D008647:Mesocricetus; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014425:Turpentine; D015054:Zymosan
chemical_list: D008078:Cholesterol, LDL; D008070:Lipopolysaccharides; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; C099252:oxidized low density lipoprotein; D015054:Zymosan; D014425:Turpentine